<DOC>
	<DOCNO>NCT00002232</DOCNO>
	<brief_summary>The purpose study see safe give GENEVAX-HIV , potential HIV vaccine , HIV-negative volunteer . The study also compare effect GENEVAX-HIV inject muscle effect drug inject skin .</brief_summary>
	<brief_title>A Study GENEVAX-HIV , Possible Vaccine</brief_title>
	<detailed_description>Volunteers receive either intradermal intramuscular injection GENEVAX-HIV ; humoral cellular response assess accordingly .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria Patients must : Good health . Ability understand basis HIV transmission common sexual bloodborne infection . The following parameter within normal range : Hematopoietic : total white blood cell , lymphocyte , granulocyte , platelet count , hemoglobin hematocrit . Renal : BUN creatinine , urinalysis . Hepatic : total serum bilirubin . Endocrine/Metabolic : Serum calcium , serum glucose , total serum CPK . Immunologic : total serum immunoglobulin absolute CD4 count . Hepatitis B Hepatitis C negative . Urinalysis : Normal screen dipstick esterase nitrite . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : HIVseropositive status . Any positive result antiDNA antibody consider potential clinical significance measure antiDNA antibody and/or antinuclear antibody ( ANA ) assay . Any condition , opinion principal investigator , might interfere completion study evaluation result . Known hypersensitivity bupivacaine amidetype local anesthetic ( lidocaine , dibucaine , mepivacaine , prilocaine ) history anaphylaxis serious adverse reaction vaccine . Concurrent Medication : Excluded : Any medication may affect immune function exception low dos nonprescriptionstrength NSAIDS , aspirin , acetaminophen acute condition headache trauma . Patients follow prior condition exclude : HIVseropositive . Known suspected history impairment abnormality immune functioning . Exposure potentiallyinfective HIV fluid within prior 6 month test positive HIV time . History prior disease therapy would affect immune function include : Prior malignancy , except curativelytreated basal cell squamous cell carcinoma situ cervix . Immunodeficiency autoimmune disease . Acute infection recent ( within 6 month ) history chronic infection . History serious allergic reaction substance require hospitalization emergent medical care ( e.g. , StevensJohnson syndrome , bronchospasm , hypotension ) . Prior Medication : Excluded : Cytotoxic chemotherapy may affect immune function . Prior Treatment : Excluded : Previous immunization experimental vaccine direct HIV receipt experimental agent within 30 day prior enrollment . Receipt blood product immunoglobulin within 6 month prior enrollment . Exposure live attenuate vaccine within 60 day study . Radiotherapy may affect immune function . Risk Behavior : Excluded : Active drug alcohol abuse uncontrolled ( unstable ) psychiatric disorder , opinion investigator , would interfere study participation . Higher intermediaterisk sexual behavior ( AVEG criterion )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 1999</verification_date>
	<keyword>Injections , Intradermal</keyword>
	<keyword>Injections , Intramuscular</keyword>
	<keyword>HIV Antibodies</keyword>
	<keyword>Immunity , Cellular</keyword>
	<keyword>AIDS Vaccines</keyword>
	<keyword>HIV Seronegativity</keyword>
	<keyword>Dose-Response Relationship , Immunologic</keyword>
	<keyword>Vaccines , DNA</keyword>
	<keyword>Immunity , Mucosal</keyword>
</DOC>